AU2014339000B2 - Sulfated polysaccharides for use in the treatment of cancer - Google Patents

Sulfated polysaccharides for use in the treatment of cancer Download PDF

Info

Publication number
AU2014339000B2
AU2014339000B2 AU2014339000A AU2014339000A AU2014339000B2 AU 2014339000 B2 AU2014339000 B2 AU 2014339000B2 AU 2014339000 A AU2014339000 A AU 2014339000A AU 2014339000 A AU2014339000 A AU 2014339000A AU 2014339000 B2 AU2014339000 B2 AU 2014339000B2
Authority
AU
Australia
Prior art keywords
platelets
cell
cells
heparin
sulfated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014339000A
Other languages
English (en)
Other versions
AU2014339000A1 (en
Inventor
Hans-Ake Fabricius
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cell Receptor SA
Original Assignee
Cell Receptor SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cell Receptor SA filed Critical Cell Receptor SA
Publication of AU2014339000A1 publication Critical patent/AU2014339000A1/en
Application granted granted Critical
Publication of AU2014339000B2 publication Critical patent/AU2014339000B2/en
Assigned to Cell Receptor AG reassignment Cell Receptor AG Request to Amend Deed and Register Assignors: CELL RECEPTOR GMBH
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0021—Dextran, i.e. (alpha-1,4)-D-glucan; Derivatives thereof, e.g. Sephadex, i.e. crosslinked dextran
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0057—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Xylans, i.e. xylosaccharide, e.g. arabinoxylan, arabinofuronan, pentosans; (beta-1,3)(beta-1,4)-D-Xylans, e.g. rhodymenans; Hemicellulose; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0069—Chondroitin-4-sulfate, i.e. chondroitin sulfate A; Dermatan sulfate, i.e. chondroitin sulfate B or beta-heparin; Chondroitin-6-sulfate, i.e. chondroitin sulfate C; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • C08B37/0078—Degradation products
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0084—Guluromannuronans, e.g. alginic acid, i.e. D-mannuronic acid and D-guluronic acid units linked with alternating alpha- and beta-1,4-glycosidic bonds; Derivatives thereof, e.g. alginates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2014339000A 2013-10-22 2014-10-22 Sulfated polysaccharides for use in the treatment of cancer Active AU2014339000B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102013111630.2 2013-10-22
DE102013111630 2013-10-22
PCT/EP2014/072620 WO2015059177A1 (en) 2013-10-22 2014-10-22 Sulfated polysaccharides for use in the treatment of cancer

Publications (2)

Publication Number Publication Date
AU2014339000A1 AU2014339000A1 (en) 2016-04-28
AU2014339000B2 true AU2014339000B2 (en) 2017-05-18

Family

ID=51795625

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014339000A Active AU2014339000B2 (en) 2013-10-22 2014-10-22 Sulfated polysaccharides for use in the treatment of cancer

Country Status (6)

Country Link
US (1) US10098906B2 (enExample)
EP (1) EP3060223B1 (enExample)
JP (1) JP6444399B2 (enExample)
AU (1) AU2014339000B2 (enExample)
CA (1) CA2926888C (enExample)
WO (1) WO2015059177A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016196256A2 (en) 2015-06-04 2016-12-08 University Of North Carolina At Greensboro Non-aromatic difluoro analogues of resorcylic acid lactones
US11191743B2 (en) * 2016-01-11 2021-12-07 Dignity Health Modulators of zinc activated cation channel
CA3072856A1 (en) 2017-08-23 2019-02-28 Cell Receptor AG Combination of a mapk/erk pathway inhibitor and a glycosaminoglycan for the treatment of cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992001003A1 (en) * 1990-07-10 1992-01-23 Board Of Regents, The University Of Texas System Glycosaminoglycan derivatives and their use as inhibitors of tumor invasiveness or metastatic profusion-ii
US20060172968A1 (en) * 2000-01-25 2006-08-03 Benito Casu Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect
WO2006083328A2 (en) * 2004-09-15 2006-08-10 Massachusetts Institute Of Technology Biologically active surfaces and methods of their use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010096466A2 (en) * 2009-02-17 2010-08-26 Novelmed Therapeutics, Inc. Methods and compositions for inhibiting cellular proliferation and surgical adhesion
CN102917711A (zh) * 2010-03-12 2013-02-06 澳大利亚国立大学 硫酸乙酰肝素替代疗法
IT1401253B1 (it) * 2010-04-23 2013-07-18 Uni Degli Studi Carlo Bo Urbino Uso del sulodexide per la riduzione delle metalloproteinasi di matrice.
TWI520740B (zh) * 2011-02-02 2016-02-11 模範健康科技私人企業有限公司 利用多硫酸化多醣之骨髓水腫（水腫）的治療
DK2861273T3 (da) * 2012-06-13 2017-11-27 Exthera Medical Corp Anvendelse af heparin og kulhydrater til behandling af cancer.
EP3131534A4 (en) * 2014-04-17 2017-12-20 Memorial Sloan Kettering Cancer Center Fucoidan nanogels and methods of their use and manufacture

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992001003A1 (en) * 1990-07-10 1992-01-23 Board Of Regents, The University Of Texas System Glycosaminoglycan derivatives and their use as inhibitors of tumor invasiveness or metastatic profusion-ii
US20060172968A1 (en) * 2000-01-25 2006-08-03 Benito Casu Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect
WO2006083328A2 (en) * 2004-09-15 2006-08-10 Massachusetts Institute Of Technology Biologically active surfaces and methods of their use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SASISEKHARAN RAM ET AL, "Roles of heparan-sulphate glycosaminoglycans in cancer", NATURE REVIEWS. CANCER, NATUR PUBLISHING GROUP, LONDON, GB, (20020701), vol. 2, no. 7, doi:10.1038/NRC842, ISSN 1474-175X, pages 521 - 528 *

Also Published As

Publication number Publication date
EP3060223B1 (en) 2017-08-30
EP3060223A1 (en) 2016-08-31
JP2016534078A (ja) 2016-11-04
AU2014339000A1 (en) 2016-04-28
US20160367589A1 (en) 2016-12-22
WO2015059177A1 (en) 2015-04-30
CA2926888C (en) 2020-03-24
JP6444399B2 (ja) 2018-12-26
CA2926888A1 (en) 2015-04-30
US10098906B2 (en) 2018-10-16

Similar Documents

Publication Publication Date Title
RS57214B1 (sr) Upotreba derivata hemijski modifikovanog heparina za bolest srpastih ćelija
EP0577716A1 (en) New non-anticoagulant heparin derivatives
CA2407065A1 (en) A complex between folic acid and polysaccharides, its preparation method and a pharmaceutical composition comprising said complex as active component
Zhang et al. Mechanistic insights into cellular immunity of chondroitin sulfate A and its zwitterionic N-deacetylated derivatives
Fan et al. Relationship of the inhibition of cell migration with the structure of ginseng pectic polysaccharides
AU2014339000B2 (en) Sulfated polysaccharides for use in the treatment of cancer
Volpi Condrosulf®: structural characterization, pharmacological activities and mechanism of action
Hou et al. Polysaccharides and their depolymerized fragments from Costaria costata: Molecular weight and sulfation-dependent anticoagulant and FGF/FGFR signal activating activities
Volpi Dermatan sulfate: Recent structural and activity data
US11559544B2 (en) Combination of a MAPK/ERK pathway inhibitor and a glycosaminoglycan for the treatment of cancer
CA2472093C (en) Use of sulfated glycosaminoglycans for establishing effective labor in women
Oreste et al. Semi-synthetic heparinoids
Franz et al. Pharmacological activities of sulfated carbohydrate polymers
Macie-Hulme Gemst,.. an, Sanderson, P
Arlov Heparin analogs created by sulfation of alginates using a chemoenzymatic strategy
Vercruysse Hyaluronan: A simple molecule with complex character
Toida Structure and Bioactivity of Acidic Polysaccharides from Natural Resources
HK1199893B (en) Use of chemically modified heparin derivates in sickle cell disease

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
HB Alteration of name in register

Owner name: CELL RECEPTOR AG

Free format text: FORMER NAME(S): CELL RECEPTOR GMBH